Broad Antiviral Activity of Carbohydrate-binding Agents Against the Four Serotypes of Dengue Virus in Monocyte-derived Dendritic Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Jul 9

PMID 21738755

Citations 23

Authors

Marijke M F Alen

Tine De Burghgraeve

Suzanne J F Kaptein

Jan Balzarini

Johan Neyts

Dominique Schols

Affiliations

Soon will be listed here.

Abstract

Background: Dendritic cells (DC), present in the skin, are the first target cells of dengue virus (DENV). Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is present on DC and recognizes N-glycosylation sites on the E-glycoprotein of DENV. Thus, the DC-SIGN/E-glycoprotein interaction can be considered as an important target for inhibitors of viral replication. We evaluated various carbohydrate-binding agents (CBAs) against all four described serotypes of DENV replication in Raji/DC-SIGN(+) cells and in monocyte-derived DC (MDDC).

Methodology/principal Findings: A dose-dependent anti-DENV activity of the CBAs Hippeastrum hybrid (HHA), Galanthus nivalis (GNA) and Urtica dioica (UDA), but not actinohivin (AH) was observed against all four DENV serotypes as analyzed by flow cytometry making use of anti-DENV antibodies. Remarkably, the potency of the CBAs against DENV in MDDC cultures was significantly higher (up to 100-fold) than in Raji/DC-SIGN(+) cells. Pradimicin-S (PRM-S), a small-size non-peptidic CBA, exerted antiviral activity in MDDC but not in Raji/DC-SIGN(+) cells. The CBAs act at an early step of DENV infection as they bind to the viral envelope of DENV and subsequently prevent virus attachment. Only weak antiviral activity of the CBAs was detected when administered after the virus attachment step. The CBAs were also able to completely prevent the cellular activation and differentiation process of MDDC induced upon DENV infection.

Conclusions/significance: The CBAs exerted broad spectrum antiviral activity against the four DENV serotypes, laboratory-adapted viruses and low passage clinical isolates, evaluated in Raji/DC-SIGN(+) cells and in primary MDDC.

Citing Articles

Dengue virus: pathogenesis and potential for small molecule inhibitors.

Chauhan N, Gaur K, Asuru T, Guchhait P Biosci Rep. 2024; 44(8).

PMID: 39051974 PMC: 11327219. DOI: 10.1042/BSR20240134.

Molecular Mechanisms of Antiviral Agents against Dengue Virus.

Lee M, Wu Y, Poh C Viruses. 2023; 15(3).

PMID: 36992414 PMC: 10056858. DOI: 10.3390/v15030705.

Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.

Vanhulle E, Dhuys T, Provinciael B, Stroobants J, Camps A, Noppen S Front Cell Infect Microbiol. 2022; 12:989534.

PMID: 36111239 PMC: 9468479. DOI: 10.3389/fcimb.2022.989534.

Flavivirus Entry Inhibitors.

Yu Y, Si L, Meng Y Adv Exp Med Biol. 2022; 1366:171-197.

PMID: 35412141 DOI: 10.1007/978-981-16-8702-0_11.

A Preliminary Investigation on the Antiviral Activities of the Philippine Marshmint (Mentha arvensis) Leaf Extracts against Dengue Virus Serotype 2 In Vitro.

Victoriano-Belvis A, Lao R, Morato M, Repotente E, Saclauso S, Inovejas S Kobe J Med Sci. 2022; 67(3):E98-E111.

PMID: 35367996 PMC: 9673882.

References

Bertaux C, Daelemans D, Meertens L, Cormier E, Reinus J, Peumans W . Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007; 366(1):40-50. DOI: 10.1016/j.virol.2007.04.008. View

Irie K, Mohan P, Sasaguri Y, Putnak R, Padmanabhan R . Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene. 1989; 75(2):197-211. DOI: 10.1016/0378-1119(89)90266-7. View

Whitehead S, Blaney J, Durbin A, Murphy B . Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007; 5(7):518-28. DOI: 10.1038/nrmicro1690. View

Miller J, de Wet B, deWet B, Martinez-Pomares L, Radcliffe C, Dwek R . The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 2008; 4(2):e17. PMC: 2233670. DOI: 10.1371/journal.ppat.0040017. View

Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W . Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8. PMC: 3837288. DOI: 10.1126/science.1185181. View

Simmons M, Burgess T, Lynch J, Putnak R . Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology. 2009; 396(2):280-8. DOI: 10.1016/j.virol.2009.10.023. View

Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A . Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2002; 101(2):758-65. DOI: 10.1182/blood-2002-05-1447. View

Hoorelbeke B, Huskens D, Ferir G, Francois K, Takahashi A, Van Laethem K . Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother. 2010; 54(8):3287-301. PMC: 2916299. DOI: 10.1128/AAC.00254-10. View

Chen Y, Maguire T, Hileman R, Fromm J, Esko J, Linhardt R . Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997; 3(8):866-71. DOI: 10.1038/nm0897-866. View

10.

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

11.

Taylor P, Gordon S, Martinez-Pomares L . The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol. 2005; 26(2):104-10. DOI: 10.1016/j.it.2004.12.001. View

12.

Marovich M, Grouard-Vogel G, Louder M, Eller M, Sun W, Wu S . Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc. 2002; 6(3):219-24. DOI: 10.1046/j.0022-202x.2001.00037.x. View

13.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

14.

Palmer D, Sun P, Celluzzi C, Bisbing J, Pang S, Sun W . Differential effects of dengue virus on infected and bystander dendritic cells. J Virol. 2005; 79(4):2432-9. PMC: 546567. DOI: 10.1128/JVI.79.4.2432-2439.2005. View

15.

Lozach P, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier J . Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem. 2005; 280(25):23698-708. DOI: 10.1074/jbc.M504337200. View

16.

Halstead S . Dengue. Lancet. 2007; 370(9599):1644-52. DOI: 10.1016/S0140-6736(07)61687-0. View

17.

Tacken P, de Vries I, Torensma R, Figdor C . Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007; 7(10):790-802. DOI: 10.1038/nri2173. View

18.

Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, Takahashi A . Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A. 2009; 106(37):15633-8. PMC: 2734881. DOI: 10.1073/pnas.0907572106. View

19.

Balzarini J, Van Damme L . Microbicide drug candidates to prevent HIV infection. Lancet. 2007; 369(9563):787-797. DOI: 10.1016/S0140-6736(07)60202-5. View

20.

Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi J, Park C . Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol. 2005; 175(7):4265-73. PMC: 1378112. DOI: 10.4049/jimmunol.175.7.4265. View